Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 26 member 4 (SLC26A4), commonly known as pendrin, is an electroneutral anion exchanger that transports chloride, bicarbonate, iodide, and other monovalent anions across cell membranes. It is primarily expressed in the epithelial cells of the inner ear, thyroid gland, kidneys, and inflamed airways. In the inner ear, pendrin plays a critical role in maintaining endolymphatic fluid volume and pH homeostasis. In the thyroid, it mediates iodide efflux across the apical membrane, which is essential for thyroid hormone synthesis. In the kidneys, it participates in acid-base balance and chloride reabsorption. Loss-of-function mutations in the SLC26A4 gene are a major cause of Pendred syndrome and non-syndromic sensorineural hearing loss (DFNB4), characterized by deafness, enlarged vestibular aqueduct, and goiter. Conversely, upregulation of pendrin in the airways is associated with inflammatory lung diseases, such as asthma and cystic fibrosis, where it contributes to airway hyperreactivity and mucus production. Consequently, pendrin has emerged as a therapeutic target. Small-molecule inhibitors (such as PDSinh-A01 and YS-01) are being developed to increase airway surface liquid volume in inflammatory lung diseases and to potentiate loop diuretics in hypertension or edema. Meanwhile, gene therapies (such as SKY-PEN) are under development to restore functional pendrin expression in patients with genetic hearing loss.
Inhibition of anion exchange activity (for inflammatory airway diseases and diuretic potentiation); Gene replacement to restore functional protein expression (for genetic hearing loss)
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 26 member 4 (SLC26A4).